Zacks Investment ResearchT3·20d ago
DCTH Delcath Systems Inc
XNAS
14.88
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
DCTH
$14.88
—
Key stats
$14.88
- 52-Week Range
- $8.12 – $17.42
- YTD
- +49.55%
- IV Rank (30D)
- 95.07
- Straddle Price
- $5.00
- P/C Vol Ratio
- 0.14
- Market Cap
- $0.5B
- Open
- $14.59
- Day Range
- $14.59 – $14.88
- Volume
- 21,579
- Prev Close
- $14.70
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.05 |
| Cost of Equity (CAPM) | 10.94% (VRP-adj) |
| WACC | 10.95% |
| Volatility Risk Premium | +112.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | 0.4% |
| Book / Price | 21.2% |
| Gross Margin (TTM) | 87.1% |
| FCF Margin (TTM) | 18.3% |
| Debt / Equity | 0.00 |
| Quality Score | 5/6 — high quality (12y DCF) |
| Market-Implied Growth | +17.4% (reverse-DCF on current price) |
| SMA 50 | $16.00 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $15.27 |
| Bollinger Width / SMA20 | 92.9% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $1B |
Peers used for multiples: ABEO, ACHV, CLDX, CMPS, CORT, KYTX, MIST, PHAT
60-Day Conviction
87%
20-Day Fair Value
≈ by Nov 20, 2026
$14.95
α +1.2%
rank 100%
conviction
68%
40-Day Fair Value
≈ by Dec 21, 2026
$15.10
α +2.2%
rank 100%
conviction
66%
60-Day Fair Value
≈ by Jan 19, 2027
$15.29
α +3.4%
rank 100%
conviction
87%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $30.02 | 56% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $10.36 | 22% | median 3.3× · 5 peers |
| Peer P/S | $40.84 | 22% | median 15.2× · 5 peers |
| Market Anchor (SMA50) | $16.00 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $14.27 | 0% | 7 strikes · skew -0.65 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.5B
- Employees
- 156
- List Date
- 2000-10-19
- CIK
- 0000872912
- Next Earnings
- 2026-11-03 (Pre-Market)
- EPS Forecast
- ($0.10) (1 est.)
- Headquarters
- Queensbury, NY
- Homepage
- https://www.delcath.com
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatme…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -4.49% | -13.21% | 7.80% | 16.69% | 23.71% | -0.40% | 5.02% |
| Feb | 6.51% | -6.64% | 33.69% | -11.65% | -8.28% | -10.82% | 0.47% |
| Mar | -37.93% | 4.07% | 18.80% | 13.84% | -4.64% | 3.92% | -0.32% |
| Apr | -9.31% | -3.36% | -3.21% | 8.56% | -4.22% | 8.81% | -0.45% |
| May | -7.92% | -21.20% | 37.48% | 30.56% | 34.19% | -0.19% | 12.15% |
| Jun | 11.89% | -11.14% | -22.37% | 24.37% | -16.56% | 18.77% | 0.83% |
| Jul | -19.37% | 6.92% | -21.65% | 4.36% | -15.75% | -4.68% | -8.36% |
| Aug | 0.30% | -0.12% | 9.29% | 34.31% | 4.06% | 26.23% | 12.35% |
| Sep | 5.99% | -21.57% | -16.67% | -14.49% | -1.38% | -2.62% | -8.46% |
| Oct | 13.37% | -11.93% | -15.55% | 22.91% | -8.56% | -4.09%* | -0.64% |
| Nov | -13.05% | -0.35% | -11.58% | 13.14% | 1.89% | -- | -1.99% |
| Dec | -20.19% | 25.00% | 44.44% | -4.75% | 5.43% | -- | 9.99% |
| Total | -60.21% | -47.57% | 36.11% | 228.44% | -1.45% | 33.80% | 31.52% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $15.21
SMA 50: $15.96
SMA 200: $12.22
Current: $14.85
EMA 12: $14.92
EMA 26: $15.24
MACD: -0.3252 | Signal: -0.0520
BEARISH
ADX (14): 22.62
WEAK TREND
+DI: 15.34
−DI: 25.55
Momentum Oscillators
RSI (14): 44.82
NEUTRAL
Stoch %K: 39.09
Stoch %D: 30.06
Williams %R: -56.85
Volume & Volatility
BB Upper: $16.24
BB Lower: $14.18
NEUTRAL
OBV: -4,350,930
Vol SMA 20: 288,022
Vol ROC: -94.98%
ATR: $0.51
True Range: $0.29
HV 20: 41.4%
HV 30: 36.9%
HV 60: 58.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers and Primary Risks:
- Technical indicators suggest a potential uptrend, with MACD and RSI in bullish zones
- Volatility is high, which may impact trading decisions
- Recent news headlines are generally neutral, without any significant market-moving events
Investment Thesis: Delcath Systems (DCTH) shows signs of strengthening momentum, but its high volatility and beta make it a riskier investment. The stock's recent price movement could be attributed to various technical indicators in bullish zones.
Recent News Sentiment Impact: Neutral news headlines have not had a significant impact on the stock's price movement.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Uptrend
- Long-term (3-12 months): Sideways trend
Support/Resistance Levels:
- Upper Bollinger Band: $11.82
- Middle Bollinger Band: $11.07
- Lower Bollinger Band: $10.33
Momentum Signals:
- RSI interpretation: Neutral (48.66)
- MACD signal: Bullish (0.17 / Signal: -0.08 / Histogram: 0.25)
- Bollinger Bands position: Neutral (squeeze)
Volume Analysis: Volume SMA 20 is declining, indicating a potential distribution.
News & Sentiment Analysis
Recent Headlines Summary: Neutral news headlines dominate the recent news cycle.
Sentiment Assessment: Neutral (average sentiment of recent news articles)
Catalyst Identification: No significant upcoming events or catalysts have been identified.
Market Narrative: The market narrative is driven by neutral news headlines, which do not significantly impact the stock's price movement.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to the market (beta: 1.77)
Volatility Regime: High volatility regime (stock moves more than the market)
Options Market Signals: IV rank is medium, indicating historically high volatility. The put/call volume ratio is bullish.
Downside Protection: Support levels and risk management considerations are crucial in a high-risk environment.
Market Context & Positioning
Sector Performance: Delcath Systems operates within the healthcare sector, which has been performing relatively well recently.
Institutional Activity: Institutional interest is moderate, with an open interest of 1,310 calls vs 46 puts.
Correlation Analysis: The stock exhibits a moderate correlation (0.43) with the broader market.
Relative Valuation: The stock's price movement can be attributed to various technical indicators in bullish zones.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $11.82
- Middle Bollinger Band: $11.07
- Lower Bollinger Band: $10.33
Breakout/Breakdown Levels: No significant levels have been identified, but caution is advised due to high volatility.
Time-Sensitive Catalysts: No imminent earnings dates or catalysts have been identified.
Risk Management: Stop-loss levels and position sizing considerations are crucial in a high-risk environment.
By analyzing the provided data, it becomes clear that Delcath Systems (DCTH) exhibits mixed signals. While technical indicators suggest a potential uptrend, volatility is high, which may impact trading decisions. The stock's recent price movement can be attributed to various technical indicators in bullish zones. However, the neutral news headlines have not had a significant impact on the stock's price movement. It is essential to consider the risks and volatility before making any investment decisions.
Note: This report focuses solely on providing a comprehensive analysis of the provided data. It does not provide buy/sell advice or recommendations.
Generated
News
All DCTH news →
Zacks Investment ResearchT3·28mo ago
Zacks Investment ResearchT3·28mo ago
Zacks Investment ResearchT3·29mo ago
Zacks Investment ResearchT3·29mo ago
Zacks Investment ResearchT3·29mo ago
BenzingaT3·29mo ago
Zacks Investment ResearchT3·29mo ago
Zacks Investment ResearchT3·30mo ago
Zacks Investment ResearchT3·31mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
12 of 15 under expected move
Avg Expected Move
20.42%
Avg Actual Move
8.82%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-12 | Pre-Market | 39.34% | 0.75% | 0.02x | Within |
| 2023-11-13 | Pre-Market | 18.98% | 1.02% | 0.05x | Within |
| 2024-03-26 | Pre-Market | 30.04% | 1.07% | 0.04x | Within |
| 2024-05-14 | Pre-Market | 14.81% | 30.93% | 2.09x | Exceeded |
| 2024-08-05 | Pre-Market | 34.48% | 2.46% | 0.07x | Within |
| 2024-10-17 | Pre-Market | 11.57% | 7.57% | 0.65x | Within |
| 2024-11-08 | After-Close | 10.40% | 9.95% | 0.96x | Within |
| 2025-01-13 | Pre-Market | 15.24% | 11.41% | 0.75x | Within |
| 2025-05-08 | Pre-Market | 17.23% | 23.64% | 1.37x | Exceeded |
| 2025-08-06 | Pre-Market | 20.44% | 1.14% | 0.06x | Within |
| 2025-10-20 | Pre-Market | 35.92% | 4.59% | 0.13x | Within |
| 2026-01-12 | After-Close | 7.29% | 1.26% | 0.17x | Within |
| 2026-02-26 | Pre-Market | 17.63% | 11.85% | 0.67x | Within |
| 2026-05-07 | After-Close | 14.90% | 2.14% | 0.14x | Within |
| 2026-08-06 | Pre-Market | 18.01% | 22.49% | 1.25x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
DCTH Options Activity & IV Rank
DCTH IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 120.2%
7-DTE IV: —
Expected Move: $5.00
7-DTE Move: $5.00
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 309
Put Volume: 43
P/C Volume: 0.139
BULLISH
Call OI: 1,656
Put OI: 257
P/C OI: 0.155
Total OI: 1,913
ATM Options Pricing
ATM Call: $2.55
ATM Put: $2.45
Call %: 17.1%
Put %: 16.5%
Chain Summary
Chain Volume: 712
Chain OI: 2,571
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 47th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
47%
vs own history
GEX tilt
+0.66
OI-weighted, today
Vanna tilt
+0.80
δ-sensitivity to IV
Charm tilt
-0.84
δ-decay vs time
Vanna tilt +0.80: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.84: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 155.0% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)95.1HighOct 22
Straddle Price (30 DTE)$5.00Oct 22
Beta Analysis
Risk Metrics
Beta: 1.3191
Alpha: 28.51%
Correlation: 0.3354
R-Squared: 11.2%
Stock Volatility: 50.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own DCTH
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $7.1M | #1825 of 3716 | -3.7% | 13F | |
| Citadel Hedge fund Ken Griffin | $189K | #5523 of 6285 | -80.5% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $10K | #4034 of 4729 | +36.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
DCTH Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 38,939,765 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$4.35M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $1.26M | 28.95% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $1.02M | 23.51% | 2026-06-30 |
| 3 | Stonepine Capital Management, LLC | $1.00M | 22.99% | 2026-06-30 |
| 4 | Wolverine Trading, LLC Custodian | $479.60K | 11.03% | 2025-09-30 |
| 5 | Citadel Advisors LLC Custodian | $334.89K | 7.70% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $120.86K | 2.78% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $69.25K | 1.59% | 2026-06-30 |
| 8 | Private Wealth Advisors, LLC | $62.95K | 1.45% | 2026-06-30 |
4 filers$2.50M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $1.89M | 75.92% | 2026-06-30 |
| 2 | Wolverine Trading, LLC Custodian | $209.28K | 8.39% | 2025-09-30 |
| 3 | Citadel Advisors LLC Custodian | $202.70K | 8.12% | 2026-06-30 |
| 4 | Susquehanna International Group, LLP Custodian | $188.85K | 7.57% | 2026-06-30 |
DCTH Insider Trading (Form 4)
Latest: 2026-10-14Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Rosalind Advisors, Inc. | Director | Mixed | −71,625 | — | EDGAR | |
| 2026-05-14 | Elizabeth Czerepak | Director | Grant (A) | +22,500 opt | — | EDGAR | |
| 2026-05-14 | Gil Aharon | Director | Grant (A) | +22,500 opt | — | EDGAR | |
| 2026-05-14 | Steven A J Salamon | Director | Grant (A) | +22,500 opt | — | EDGAR | |
| 2026-05-14 | John Richard Sylvester | Director | Grant (A) | +22,500 opt | — | EDGAR | |
| 2026-05-14 | Bridget A Martell | Director | Grant (A) | +22,500 opt | — | EDGAR | |
| 2026-03-06 | Sandra Pennell | Chief Financial Officer | Buy (P) | +5,533 | $9.04 | $50.0K | EDGAR |
| 2026-03-03 | Gerard J Michel | CHIEF EXECUTIVE OFFICER | Buy (P) | +11,200 | $8.96 | $100.3K | EDGAR |
| 2026-02-18 | Vojo Vukovic | CHIEF MEDICAL OFFICER | Grant (A) | +84,750 RSU | — | EDGAR | |
| 2026-02-18 | David L. Hoffman | GEN'L COUNSEL, CCO & SECY | Grant (A) | +84,750 RSU | — | EDGAR | |
| 2026-02-18 | Gerard J Michel | CHIEF EXECUTIVE OFFICER | Grant (A) | +292,500 opt | — | EDGAR | |
| 2026-02-18 | Sandra Pennell | Chief Financial Officer | Grant (A) | +84,750 RSU | — | EDGAR | |
| 2026-02-18 | Martha S. Rook | CHIEF OPERATING OFFICER | Grant (A) | +84,750 RSU | — | EDGAR | |
| 2026-02-18 | Kevin Muir | GM INTERVENTIONAL ONCOLOGY | Grant (A) | +84,750 opt | — | EDGAR | |
| 2025-11-25 | John Richard Sylvester | Director | Buy (P) | +4,386 | $8.89 | $39.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
DCTH Insider Holdings
9 insiders · @ $14.85
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Steven A J Salamon | Director | 4,534,493 | $67.34M | $503.8K | 31 | 2026-05-14 |
| 2 | Gil Aharon | Director | 4,483,178 | $66.58M | $136.7K | 22 | 2026-05-14 |
| 3 | Rosalind Advisors, Inc. | Director | 3,417,095 | $50.74M | $6.84M | 21 | 2026-10-14 |
| 4 | Gerard J Michel | CHIEF EXECUTIVE OFFICER | 342,034 | $5.08M | $1.47M | 23 | 2026-03-03 |
| 5 | Vojo Vukovic | CHIEF MEDICAL OFFICER | 168,882 | $2.51M | $268.8K | 7 | 2026-02-18 |
| 6 | Sandra Pennell | Chief Financial Officer | 77,018 | $1.14M | $122.9K | 7 | 2026-03-06 |
| 7 | David L. Hoffman | GEN'L COUNSEL, CCO & SECY | 74,330 | $1.10M | $99.2K | 7 | 2026-02-18 |
| 8 | Kevin Muir | GM INTERVENTIONAL ONCOLOGY | 18,582 | $275.9K | $0 | 6 | 2026-02-18 |
| 9 | John Richard Sylvester | Director | 14,936 | $221.8K | $89.6K | 9 | 2026-05-14 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
DCTH Board & Officers
As of SEC filings through Oct 14, 2026Directors 7
- John Richard Sylvester · since Jul 24, 2019
- Elizabeth Czerepak · since Feb 14, 2020
- Gerard J Michel · since Oct 1, 2020
- Steven A J Salamon · listed since Nov 2020
- Gil Aharon · listed since Nov 2020
- Rosalind Advisors, Inc. (entity) · listed since Nov 2020
- Bridget A Martell · since May 23, 2024
Officers 6
- Gerard J Michel · Chief Executive Officer · listed since Jul 2022
- Sandra Pennell · Chief Financial Officer · listed since Feb 2025
- Martha S. Rook · Chief Operating Officer · since Mar 18, 2024
- Vojo Vukovic · Chief Medical Officer · since Jun 19, 2023
- David L. Hoffman · Gen'l Counsel, Cco & Secy · listed since Jan 2024
- Kevin Muir · Gm Interventional Oncology · listed since Mar 2024
Changes in the last 10 years (29)
| Feb 7, 2025 | Sandra Pennell listed as Chief Financial Officer (previously SVP of Finance, Pfo and Pao) in SEC filings |
| May 23, 2024 | Bridget A Martell became a director |
| Mar 19, 2024 | Kevin Muir listed as Gm Interventional Oncology (previously VP Commercial Operations) in SEC filings |
| Mar 18, 2024 | Martha S. Rook became Chief Operating Officer |
| Feb 20, 2024 | Anthony Dias reported in an SEC filing no longer being Vice President of Finance |
| Feb 12, 2024 | The company announced the departure of John Purpura as Chief Operating Officer in an SEC filing |
| Feb 9, 2024 | The company announced the departure of Roger G Phd Stoll from the board in an SEC filing |
| Jan 26, 2024 | David L. Hoffman listed as Gen'l Counsel, Cco & Secy (previously General Counsel, Chief Compliance Officer and Secretary) in SEC filings |
| Jun 19, 2023 | Vojo Vukovic became Chief Medical Officer |
| Jun 1, 2023 | Sandra Pennell became SVP of Finance, Pfo and Pao |
| Jul 21, 2022 | Gerard J Michel listed as Chief Executive Officer (previously Chief Executive Officer and Interim Principal Accounting Officer) in SEC filings |
| May 4, 2022 | Kevin Muir became VP Commercial Operations |
| May 4, 2022 | David L. Hoffman became General Counsel, Chief Compliance Officer and Secretary |
| May 4, 2022 | Anthony Dias became Vice President of Finance |
| Apr 4, 2022 | Johnny John became Senior Vice President Clinical Development and Medical Affairs |
| Dec 6, 2021 | Gerard J Michel listed as Chief Executive Officer and Interim Principal Accounting Officer (previously Chief Executive Officer) in SEC filings |
| Nov 20, 2020 | John Purpura listed as Chief Operating Officer (previously EVP, Global Operations) in SEC filings |
| Nov 16, 2020 | Rosalind Advisors, Inc. first listed as a director in an SEC filing |
| Nov 16, 2020 | Gil Aharon first listed as a director in an SEC filing |
| Nov 13, 2020 | Steven A J Salamon first listed as a director in an SEC filing |
| Oct 1, 2020 | Gerard J Michel became a director |
| Oct 1, 2020 | Gerard J Michel became Chief Executive Officer |
| Jun 11, 2020 | Christine Padula became interim principal accounting officer |
| Feb 14, 2020 | Elizabeth Czerepak became a director |
| Jul 26, 2019 | Jennifer K. Simpson first listed as a director in an SEC filing |
| Jul 24, 2019 | John Richard Sylvester became a director |
| Feb 5, 2019 | Simon Pedder first on file as a director |
| Oct 23, 2018 | John Purpura listed as EVP, Global Operations (previously EVP, Regulatory Affairs) in SEC filings |
| Jun 29, 2017 | Barbra Keck listed as Chief Financial Officer (previously Senior VP, Finance) in SEC filings |
Not reported recently (7)
- Johnny John · Last reported as Senior Vice President Clinical Development and Medical Affairs in an SEC filing dated Jan 26, 2024
- Christine Padula · Last reported as interim principal accounting officer in an SEC filing dated Oct 19, 2021
- Barbra Keck · Last reported as Chief Financial Officer in an SEC filing dated May 8, 2020
- Jennifer K. Simpson · Last reported as President & CEO in an SEC filing dated May 8, 2020
- Marco Taglietti · Last reported as a director in an SEC filing dated May 8, 2020
- William Dodge Rueckert · Last reported as a director in an SEC filing dated May 8, 2020
- Simon Pedder · Last reported as a director in an SEC filing dated Feb 5, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
DCTH Proposed Insider Sales (Form 144)
Latest: 2024-07-09
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-07-09 | STOLL ROGER G PHD | Retired | 1,000 | $7.3K | 2024-07-09 | Merrill Lynch | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
33 ETFs hold DCTH
25 shown · $49.90M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $14.2M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $10.8M | $75.1B | 2026-10-20 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $5.0M | — | 2026-09-30 |
| 4 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $3.4M | $13.7B | 2026-10-20 |
| 5 | SURI Simplify Propel Opportunities ETF | Nport | 4.26% | $3.3M | — | 2026-06-30 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $2.7M | — | 2026-09-30 |
| 7 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $1.8M | — | 2026-10-20 |
| 8 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.11% | $1.3M | $1.2B | 2026-10-20 |
| 9 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.3M | — | 2026-10-20 |
| 10 | XHE State Street® SPDR® S&P® Health Care Equipment ETF | SPDR (State Street) | 0.82% | $1.2M | $149.3M | 2026-10-20 |
| 11 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.07% | $733,542 | $1.0B | 2026-10-20 |
| 12 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $666,045 | — | 2026-10-20 |
| 13 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $647,285 | $97.4B | 2026-10-20 |
| 14 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.02% | $646,768 | $3.1B | 2026-10-20 |
| 15 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $578,917 | $13.6B | 2026-10-20 |
| 16 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.24% | $386,075 | — | 2026-05-31 |
| 17 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.03% | $362,599 | — | 2026-09-30 |
| 18 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $320,617 | — | 2026-10-20 |
| 19 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $206,447 | — | 2026-10-21 |
| 20 | AFSM First Trust Active Factor Small Cap ETF | First Trust | 0.10% | $134,405 | $129.1M | 2026-10-20 |
| 21 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.02% | $133,731 | — | 2026-06-30 |
| 22 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.00% | $71,402 | — | 2026-09-30 |
| 23 | DFSU Dimensional US Sustainability Core 1 ETF | Dimensional | 0.00% | $48,664 | $2.4B | 2026-10-20 |
| 24 | LITL Simplify Piper Sandler US Small-Cap PLUS Income ETF | Nport | 0.67% | $45,878 | — | 2026-06-30 |
| 25 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $39,526 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
1478.00
TTM Diluted EPS
$0.01
TTM Revenue
$95.42M
TTM Net Income
$532.00K
TTM Op. Cash Flow
$19.59M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $29.13M | $2.67M | $0.07 | $5.71M |
| Q1 '26 | 2026-03-31 | $24.99M | $-1.07M | $-0.03 | $857.00K |
| Q4 '25 | 2025-12-31 | $20.73M | $-1.90M | $-0.05 | $8.25M |
| Q3 '25 | 2025-09-30 | $20.56M | $830.00K | $0.02 | $4.77M |
| Q2 '25 | 2025-06-30 | $24.16M | $2.70M | $0.07 | $7.29M |
| Q1 '25 | 2025-03-31 | $19.78M | $1.07M | $0.03 | $2.20M |
| Q4 '24 | 2024-12-31 | $15.10M | $-3.40M | $-0.09 | $-1.01M |
| Q3 '24 | 2024-09-30 | $11.20M | $1.86M | $0.06 | $-3.64M |
| Q2 '24 | 2024-06-30 | $7.77M | $-13.74M | $-0.48 | $-4.45M |
| Q1 '24 | 2024-03-31 | $3.14M | $-11.11M | $-0.45 | $-9.58M |
| Q4 '23 | 2023-12-31 | $539.00K | $-11.14M | $-0.33 | $-8.18M |
| Q3 '23 | 2023-09-30 | $434.00K | $-20.34M | $-1.14 | $-9.16M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
1478.00
P/B
4.75
P/S
6.03
EV/EBITDA
—
EV/Sales
5.53
ROE
0.4%
ROA
0.4%
Div Yield
0.00%
FCF Yield
3.40%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$575.53M
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.95M
SI % of Float
7.38%
Days to Cover
5.37
Short Vol Ratio
53.6%
Free Float
26.37M
Float %
76.0%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14